Phase 2Completed

A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.

Sponsor
Solvay Pharmaceuticals (Industry)
Enrollment
2,288 enrolled
Conditions
Patients With Metabolic Syndrome
Interventions
Fenofibrate /Metformin; Fenofibrate /Metformin; Fenofibrate /Metformin; Fenofibrate /Metformin; Fenofibrate /Metformin; Fenofibrate /Metformin; Placebo
Ages
adults, older adults
Registry
NCT00703755

Full record on ClinicalTrials.gov

From the registry

The purpose of this study was to study the effect of different combinations of fenofibrate and metformin on the cluster of metabolic syndrome (MetS) biochemical abnormalities, and to determine the dose combination allowing normalization of MetS patients.

Primary outcomes

  • The percentage of normalized patients at V4 (fasting glucose < 6.1 mmol/L, TG < 1.69 mmol/L and HDL-C >= 1.03 mmol/L in males and >= 1.29 mmol/L in females)

History

  1. Last registry update

  2. Registered

  3. Primary completion

  4. Started